The collaboration will leverage Immunocore’s ImmTAC technology directed towards the cancerous cells avoiding damage to healthy cells and the intracellular changes that occur during cancer or viral infection could be recognized by ImmTACs by exploiting the power of T Cell Receptors.
Genentech Partnering senior vice president James Sabry said, "We believe Immunocore is the leading company in T Cell receptor biology and drug development and an excellent partner for Genentech in this area."
According to the deal, Immunocore will earn an initiation fee of between $10m and $20m per programme, besides more than $300m in development and commercial milestone payments for each target programme and significant tiered royalties.
Immunocore chief scientific officer and founder Bent Jakobsen said, "Our collaboration with Genentech generating ImmTACs against these novel targets allows us jointly to explore the true potential of the technology."